Cargando…

Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample

Biological bases of autism spectrum disorder (ASD) include both genetic and epigenetic causes. Patients with ASD show anomalies in the profile of certain plasma amino acids, including neuroactive amino acids. Monitoring plasma amino acids may be relevant for patient care and interventions. We evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Randazzo, Martina, Prato, Adriana, Messina, MariaAnna, Meli, Concetta, Casabona, Antonino, Rizzo, Renata, Barone, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955282/
https://www.ncbi.nlm.nih.gov/pubmed/36832540
http://dx.doi.org/10.3390/children10020412
_version_ 1784894312456126464
author Randazzo, Martina
Prato, Adriana
Messina, MariaAnna
Meli, Concetta
Casabona, Antonino
Rizzo, Renata
Barone, Rita
author_facet Randazzo, Martina
Prato, Adriana
Messina, MariaAnna
Meli, Concetta
Casabona, Antonino
Rizzo, Renata
Barone, Rita
author_sort Randazzo, Martina
collection PubMed
description Biological bases of autism spectrum disorder (ASD) include both genetic and epigenetic causes. Patients with ASD show anomalies in the profile of certain plasma amino acids, including neuroactive amino acids. Monitoring plasma amino acids may be relevant for patient care and interventions. We evaluated the plasma amino acid profile in samples extracted from dry blood spots by electrospray ionization-tandem mass spectrometry. Fourteen amino acids and eleven amino acid ratios were examined in patients with ASD and intellectual disability (ID), and neurotypical control subjects (TD). The amino acid profile in the ASD group showed reduced levels of ornithine (p = 0.008), phenylalanine (p = 0.042) and tyrosine (p = 0.013). The statistically significant amino acid ratios were Leu+Val/Phe+Tyr (p = 0.002), Tyr/Leu (p = 0.007) and Val/Phe (p = 0.028), such differences remaining significant only in the comparison between ASD and TD. Finally, a positive correlation emerged between the score of the restricted and repetitive behavior on ADOS-2 and the citrulline levels in the ASD group (p = 0.0047). To conclude, patients with ASD may show a distinguishable metabolic profile useful for studying their metabolic pathways in order to develop screening tests and targeted therapies.
format Online
Article
Text
id pubmed-9955282
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99552822023-02-25 Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample Randazzo, Martina Prato, Adriana Messina, MariaAnna Meli, Concetta Casabona, Antonino Rizzo, Renata Barone, Rita Children (Basel) Article Biological bases of autism spectrum disorder (ASD) include both genetic and epigenetic causes. Patients with ASD show anomalies in the profile of certain plasma amino acids, including neuroactive amino acids. Monitoring plasma amino acids may be relevant for patient care and interventions. We evaluated the plasma amino acid profile in samples extracted from dry blood spots by electrospray ionization-tandem mass spectrometry. Fourteen amino acids and eleven amino acid ratios were examined in patients with ASD and intellectual disability (ID), and neurotypical control subjects (TD). The amino acid profile in the ASD group showed reduced levels of ornithine (p = 0.008), phenylalanine (p = 0.042) and tyrosine (p = 0.013). The statistically significant amino acid ratios were Leu+Val/Phe+Tyr (p = 0.002), Tyr/Leu (p = 0.007) and Val/Phe (p = 0.028), such differences remaining significant only in the comparison between ASD and TD. Finally, a positive correlation emerged between the score of the restricted and repetitive behavior on ADOS-2 and the citrulline levels in the ASD group (p = 0.0047). To conclude, patients with ASD may show a distinguishable metabolic profile useful for studying their metabolic pathways in order to develop screening tests and targeted therapies. MDPI 2023-02-20 /pmc/articles/PMC9955282/ /pubmed/36832540 http://dx.doi.org/10.3390/children10020412 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Randazzo, Martina
Prato, Adriana
Messina, MariaAnna
Meli, Concetta
Casabona, Antonino
Rizzo, Renata
Barone, Rita
Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
title Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
title_full Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
title_fullStr Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
title_full_unstemmed Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
title_short Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
title_sort neuroactive amino acid profile in autism spectrum disorder: results from a clinical sample
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955282/
https://www.ncbi.nlm.nih.gov/pubmed/36832540
http://dx.doi.org/10.3390/children10020412
work_keys_str_mv AT randazzomartina neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample
AT pratoadriana neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample
AT messinamariaanna neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample
AT meliconcetta neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample
AT casabonaantonino neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample
AT rizzorenata neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample
AT baronerita neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample